Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.

Although interactions between estrogen and growth factor signaling pathways have been studied extensively, how growth factors and progesterone regulate each other is less clear. In this study, we found that IGF-I sharply lowers progesterone receptor (PR) mRNA and protein levels in breast cancer cells. Other growth factors, such as epidermal growth factor, also showed the same effect. The decrease of PR levels was associated with reduced PR activity. Unlike progestins, IGF-I does not utilize the proteasome for down-regulating PR. Instead, the IGF-I-mediated decrease in PR levels is via an inhibition of PR gene transcription. In addition, the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway was found to be specifically involved in this IGF-I effect. Our data also suggest that the IGF-I down-regulation of PR is not mediated via a reduction of estrogen receptor (ER) levels or activity. First, IGF-I induced ligand-independent ER activity while reducing ER-dependent PR levels. Second, whereas PR and cyclin D1 are both ER up-regulated, IGF-I increased cyclin D1 levels while decreasing PR levels. Third, constitutively active PI3K or Akt induced ER activity but reduced PR levels and activity. Taken together, our data indicate that IGF-I inhibits PR expression in breast cancer cells via the PI3K/Akt/mTOR pathway. Because low or absent PR in primary breast cancer is associated with poor prognosis and response to hormone therapy, our results suggest that low PR status may serve as an indicator of activated growth factor signaling in breast tumor cells, and therefore of an aggressive tumor phenotype and resistance against hormonal therapy.

[1]  I. H. Hamelers,et al.  Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells. , 2002, Experimental cell research.

[2]  Kenneth P. Karey,et al.  Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. , 1988, Cancer research.

[3]  Adrian V. Lee,et al.  Igf system components as prognostic markers in breast cancer , 1998, Breast Cancer Research and Treatment.

[4]  M. Dowsett,et al.  HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. , 2001, Cancer research.

[5]  M. Stampfer,et al.  Insulin receptor expression and function in human breast cancer cell lines. , 1992, Cancer research.

[6]  C. Osborne,et al.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.

[7]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[8]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[9]  C. Osborne,et al.  Biological differences among MCF-7 human breast cancer cell lines from different laboratories , 2005, Breast Cancer Research and Treatment.

[10]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[11]  Yee.  The insulin-like growth factor system as a target in breast cancer , 2022 .

[12]  McGuire Wl,et al.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.

[13]  D. Yee,et al.  Insulin-like growth factors and breast cancer. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  R. Nicholson,et al.  Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). , 2001, Endocrinology.

[15]  M. Martin,et al.  Role of insulin‐like growth factor‐I in regulating estrogen receptor‐α gene expression , 2000 .

[16]  C. Clarke,et al.  Progestin regulation of cellular proliferation. , 1990, Endocrine reviews.

[17]  G. Ho,et al.  Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  K. Horwitz,et al.  The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? , 1992, Endocrine reviews.

[19]  K. Horwitz,et al.  Convergence of Progesterone and Epidermal Growth Factor Signaling in Breast Cancer , 1998, The Journal of Biological Chemistry.

[20]  C. Gélinas,et al.  Activation of the silent progesterone receptor gene by ectopic expression of estrogen receptors in a rat fibroblast cell line. , 1993, Biochemistry.

[21]  S. Nass,et al.  The Loss of Estrogen and Progesterone Receptor Gene Expression in Human Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[22]  K. Horwitz,et al.  Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.

[23]  J. Dupont,et al.  Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects , 2001, Molecular pathology : MP.

[24]  D. Yee,et al.  Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. , 1997, The Journal of endocrinology.

[25]  M. Prisco,et al.  Differential roles of IRS‐1 and SHC signaling pathways in breast cancer cells , 1997, International journal of cancer.

[26]  C. Clarke,et al.  Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women , 1999, British Journal of Cancer.

[27]  Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. , 1993, Molecular endocrinology.

[28]  P Chambon,et al.  Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.

[29]  R. Baserga,et al.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[30]  P. Usher,et al.  Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Löning,et al.  Progesterone Receptor Isoforms, PR-B and PR-A, in Breast Cancer: Correlations with Clinicopathologic Tumor Parameters and Expression of AP-1 Factors , 2001, Hormone Research in Paediatrics.

[32]  C. Lange,et al.  Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Leroith.  Insulin-like growth factor receptors and binding proteins. , 1996, Bailliere's clinical endocrinology and metabolism.

[34]  K. Korach,et al.  Requirement of Estrogen Receptor-α in Insulin-like Growth Factor-1 (IGF-1)-induced Uterine Responses and in Vivo Evidence for IGF-1/Estrogen Receptor Cross-talk* , 2002, The Journal of Biological Chemistry.

[35]  Chris Albanese,et al.  Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression* , 2002, The Journal of Biological Chemistry.

[36]  R. Baserga.  Controlling IGF-receptor function: a possible strategy for tumor therapy. , 1996, Trends in biotechnology.

[37]  J. Downward,et al.  Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation. , 1996, The EMBO journal.

[38]  B. O’Malley,et al.  Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. , 1995, Genes & development.

[39]  K. Horwitz,et al.  Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). , 1997, Molecular endocrinology.

[40]  K. Horwitz,et al.  Transcriptional Hyperactivity of Human Progesterone Receptors Is Coupled to Their Ligand-Dependent Down-Regulation by Mitogen-Activated Protein Kinase-Dependent Phosphorylation of Serine 294 , 2001, Molecular and Cellular Biology.

[41]  O. Potapova,et al.  Growth factor PDGF‐B/v‐sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: Evidence for an autocrine, but not a paracrine, mechanism , 1996 .

[42]  T. Graubert,et al.  Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. , 2002, Developmental biology.

[43]  S. J. Clayton,et al.  Insulin-like growth factors control the regulation of oestrogen and progesterone receptor expression by oestrogens , 1997, Molecular and Cellular Endocrinology.

[44]  I. H. Hamelers,et al.  Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. , 2000, The Journal of endocrinology.

[45]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[46]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[47]  Adrian V. Lee,et al.  Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3′-Kinase Inhibition , 2000, Molecular and Cellular Biology.

[48]  L. Yamamoto,et al.  Estrogen and progesterone receptor mrna levels in primary breast cancer: Association with patient survival and other clinical and tumor features , 1994, International journal of cancer.

[49]  B. Katzenellenbogen,et al.  Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. , 1994, Endocrinology.

[50]  K. Horwitz,et al.  Convergence of Progesterone with Growth Factor and Cytokine Signaling in Breast Cancer , 1998, The Journal of Biological Chemistry.

[51]  J. Graham,et al.  Physiological action of progesterone in target tissues. , 1997, Endocrine reviews.

[52]  W. Ruan,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Insulin-Like Growth Factor I Is Essential for Terminal End Bud Formation and Ductal Morphogenesis during , 1999 .

[53]  Christine C. Hudson,et al.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. , 2000, Cancer research.

[54]  B. Katzenellenbogen,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Role for Akt in Mediating the Estrogenic Functions of Epidermal Growth Factor and Insulin-Like Growth Factor I* , 2000 .

[55]  H. Huynh,et al.  Pregnancy-dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II. , 1996, Cancer research.

[56]  G. Rena,et al.  Insulin Regulation of Insulin-like Growth Factor-binding Protein-1 Gene Expression Is Dependent on the Mammalian Target of Rapamycin, but Independent of Ribosomal S6 Kinase Activity* , 2002, The Journal of Biological Chemistry.

[57]  C. Osborne,et al.  Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. , 2001, Cancer research.

[58]  K. Horwitz,et al.  Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance , 1982, Cell.